

**DONCASTER & BASSETLAW AREA PRESCRIBING COMMITTEE (APC)**

**Action Notes and Log**

Thursday 26<sup>th</sup> September 2019 12 Noon start

**Meeting Room 3 Sovereign House**

<b>Present:</b>	Dr David Crichton Mr Alex Molyneux Mrs V-Lin Cheong Mr Rob Wise Mr Stephen Davies Mr Lee Wilson Dr Jeremy Bradley Miss Paula Whitehurst	Chair, APC Chair DCCG Head of Medicines Management DCCG Deputy Head of Medicines Management DCCG Head of Medicines Management BCCG, Deputy APC Chair Chief Pharmacist RDaSHFT Consultant Pharmacist DBTHFT DCCG Prescribing Lead Senior Medicines Management Technician (Secretary) DCCG
<b>In attendance:</b>	Mr David Smith	Data Quality and Performance Improvement/Service Manager RDaSHFT
<b>Minutes only:</b>	Dr Rupert Suckling & Dr Victor Joseph	DMBC Representatives

Agenda Ref	Subject / Action Required	Action Required By	Timescale	Status of Action (RAG) and Date
09/19/1	<b>Apologies for Absence:</b> Dr Lucy Peart, Dr Runit Shah, Mr Munashe Mvududu			
09/19/2	<b>Declarations of Interest:</b>			
09/19/2.1	<b>Fire Alarm Procedure:</b> No test planned			
09/19/2.2	<b>Notification of Any Other Business:</b> Avastin Tadalafil Opioids			
09/19/3	<b>Notes of the Meeting Held On:</b> Thursday 29th Aug 2019 were agreed as a true and accurate record and will be made available on the Medicines Management website			
09/19/4	<b>Matters Arising not on the Agenda:</b> H.Pylori feedback received from discussions at the LMC – there was a consensus of support for letters to communicate results to GPs to enable a decision about appropriate eradication treatment. Ferric Maltol will be brought back once it has been considered by the Formulary Liaison Group.			
09/19/4.1	<b>Matters Arising</b>			
01/19/8.10	Dementia SCP The amended document was discussed and it was suggested that more guidance on when to add a second medication be added and references to shared care need to be removed. Further amendments will be made and the document is to come back to APC for final approval.	<b>RDaSHFT-SD</b>	Oct 19	
04/19/19.1	Shared Care Pathway for Antipsychotics The pathway had been amended with the recommendations from Aug APC. A couple of further suggestions were discussed; Clarification that this is a Doncaster specific pathway and does not include Bassetlaw. DS confirmed that the SMI service will extend to cover all monitoring of shared care requirements, some patient cohorts out with of SMI registers such as personality disorder would not be covered under the pathway. A softening of language in parts was suggested. The importance of information on discharge and how this is	<b>RDaSHFT-SD</b>	Nov 19	

	communicated to GP's was highlighted. The go-live date is now early Dec. The document is to be amended and then shared with the LMC. Once the LMC agree they are happy with it we will address TLS status at the next APC.			
05/19/8.3	Melatonin SCP No further update. LW to follow up and bring back to APC.	DBTHFT-LW	Oct 19	
07/19/8.4	Doncaster and Bassetlaw Antimicrobial Guidelines for Primary Care The group recommend to the CCG that this is ratified with a clause that nothing should go over a 3 year period for review. RW requested for this to go on the MMG agenda to be ratified.	NHSB-RW		
09/19/5	<b>Drugs for Review</b> <b>Eculizumab</b> (Soliris) used to treat Paroxysmal nocturnal haemoglobinuria, Atypical hemolytic uremic syndrome and new indication of Neuromyelitis optica spectrum disorder has been categorised as <b>Red 1,2,8</b>	DCCG-VLC		
09/19/6	<b>Officers Actions</b> All officers' actions were agreed as proposed and will be updated on the traffic light system.	DCCG-VLC		
09/19/7	<b>Drugs for Consideration</b> <b>Valproate Semi-Sodium</b> (Belvo) used for manic episode in bipolar disorder when lithium is contraindicated or not tolerated has been classified as <b>Red 1</b> <b>Dupilumab</b> (Dupixent) used for Asthma has been classified as <b>Grey 2</b> <b>Dupilumab</b> (Dupixent) used for Atopic Dermatitis has been classified as <b>Red 1,2,8</b> <b>Benralizumab</b> (Fasenra) used for severe eosinophilic asthma has been classified as <b>Red 1,2,8</b> <b>Lorlatinib</b> (Lorviqua) used for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer has been classified as <b>Red 1,2</b> <b>Antacid and Oxetacaine</b> is to be discussed further at the next APC once more information is obtained. <b>Dapagliflozin</b> (Forxiga) used for Diabetes Mellitus Type 1 has been classified as Amber G (with link to NICE guidance)	DCCG-VLC		
09/19/8	<b>New Business</b>			

09/19/8.1	Sodium Valproate PREVENT Program The chair highlighted that this was intended to be part of the new GP contract DES. The LMC discussed this at their last meeting, feedback was that whilst referral to DRI for pregnancy prevention program (PPP) has been actioned; PPP annual declaration forms had not been actioned for some patients who were referred to Psychiatry. Steve Davies agreed to look into this.	DCCG-DC		
09/19/8.2	HRT The recent MHRA alert regarding the increased risk of breast cancer with HRT and its persistence after stopping was highlighted. The group discussed how this risk could be communicated to prescribers. It was suggested that the endocrine chapter for the formulary is to be reviewed at FLG, with the MHRA alert referred to. The group noted that there are ongoing problems with the availability of HRT products.	DCCG-DC		
09/19/8.3	Silver (AG) Dressings Categorising silver dressings was discussed due to antimicrobial content and issues with high prescribing of this in Doncaster. Silver dressings are not on the formulary. The formulary expired in 2017 and needs review. There is not a lot of evidence for the use of silver and it should be used on specific wounds. It was decided to categorise <b>silver dressings</b> as <b>Red 1,2</b> .	DCCG-VLC		
09/19/9	<b>DBTHFT D&amp;TC Update</b> The minutes of the meeting held in Sept 2019 were received by the Committee			
09/19/10	<b>Formulary Liaison Group Update</b> No minutes available			
09/19/11	<b>Doncaster Prisons Drug &amp; Therapeutic Committee update</b> No minutes available			
09/19/12	<b>RDASH FT Medicines Management Committee update</b> No minutes available			
09/19/13	<b>Barnsley Area Prescribing Committee Update</b> No minutes available			
09/19/14	<b>Rotherham Medicines Optimisation Group Update</b> The minutes of the meetings held in April, May, June and July 2019 were received by the Committee			
09/19/15	<b>Sheffield Area Prescribing Committee Update</b> No minutes available			

09/19/16	<b>Nottingham Area Prescribing Committee Update</b> No minutes available			
09/19/17	<b>SY&amp; B ICS Medicines Optimisation Work-stream Steering Group</b> No minutes available			
09/19/18	<b>Northern Regional Medicines Optimisation Committee</b> The minutes of the meeting held in June 2019 were received by the Committee			
09/19/19	<b>Any Other Business:</b>			
09/19/8.4	Avastin Information fed back on the status of Avastin following MRHA regulation statement. It is a South Yorkshire ICS work stream item so we will await guidance of how this will be taken forward.	DC		
09/19/8.5	Tadalafil A suggestion that daily dosing of Tadalafil should be via specialist. It is categorised as Green G. Guidance has been agreed with the Leger clinic and DBTHFT. It is to come back as a drug to review to the next meeting with supportive intervention to consider a change in TLS.			
09/19/8.6	Opioids The SY&B ICS are consulting with a response to what opioid messages will be cascaded. Doncaster is highlighted as one of the highest codeine prescribers nationally. It will be discussed at the 'Acute Pain meeting' also. There are links in prescribing to high social deprivation and on open prescribing data the trend is actually decreasing slightly.			
09/19/19.1	<b>Date and Time of Next Meeting:</b> 12 noon prompt Thursday 24th October 2019 Meeting Room 3 Sovereign House			

**KEY**

Completed / Closed	To Action
In Progress	To be actioned but date not yet due